Perspective - (2025) Volume 11, Issue 5
Received: 01-Oct-2025, Manuscript No. antimicro-26-183051;
Editor assigned: 03-Oct-2025, Pre QC No. P-183051;
Reviewed: 17-Oct-2025, QC No. Q-183051;
Revised: 22-Oct-2025, Manuscript No. R-183051;
Published:
29-Oct-2025
, DOI: 10.37421/2472-1212.2025.11.426
Citation: Dimitriou, Sophia. ”Novel Antimicrobial Strategies Combatting Hospital-Acquired Infections.” J Antimicrob Agents 11 (2025):426.
Copyright: © 2025 Dimitriou S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
The escalating challenge posed by hospital-acquired infections (HAIs), particularly those driven by multidrug-resistant organisms (MDROs), underscores an urgent need for the development of innovative antimicrobial agents. This review aims to highlight several promising emerging therapies that offer new avenues for combating infections where conventional antibiotics are proving increasingly ineffective. These novel strategies represent a critical shift in our approach to tackling resistant pathogens in healthcare settings [1].
One such promising avenue is phage therapy, which leverages bacteriophages, viruses that infect and kill bacteria, to target specific pathogens. This approach presents a viable alternative or adjunct to traditional antibiotics, especially for HAIs caused by resistant strains. The inherent specificity of phages minimizes collateral damage to the host microbiome, a significant advantage over broad-spectrum antibiotics [2].
Antimicrobial peptides (AMPs) are another class of agents showing considerable promise. As integral components of the innate immune system, AMPs naturally exhibit broad-spectrum activity against a range of microorganisms. Current research is focused on developing synthetic AMPs with enhanced stability and efficacy against notoriously resistant strains frequently encountered in HAIs, such as methicillin-resistant *Staphylococcus aureus* (MRSA) [3].
Complementing these biological approaches, the development of novel small molecules targeting essential bacterial pathways is actively being pursued. These inhibitors are designed to overcome existing resistance mechanisms by disrupting critical processes like DNA replication or cell wall synthesis. Promising candidates have demonstrated potent activity against Gram-positive and Gram-negative MDROs responsible for significant HAIs [4].
The growing threat of resistance to last-resort antibiotics, such as colistin, especially in Gram-negative bacteria, necessitates urgent research into alternative strategies. This includes identifying agents that can either resensitize bacteria to existing drugs or possess entirely new mechanisms of action. Efflux pump inhibitors and membrane-targeting agents are being explored for their potential in combination therapies [5].
RNA interference (RNAi) technologies offer a highly targeted therapeutic approach by specifically inhibiting bacterial virulence factors or essential genes. While significant progress has been made, challenges remain in ensuring efficient delivery systems and overcoming bacterial defense mechanisms, but the potential for HAIs is substantial [6].
Beyond direct antimicrobial action, modulating the host's microbiome is emerging as a novel strategy for preventing and treating HAIs. By fostering a healthy microbial balance, interventions like probiotics, prebiotics, and fecal microbiota transplantation (FMT) can enhance the host's resistance to colonization by opportunistic pathogens [7].
Combination therapies, employing the synergistic use of existing and novel antimicrobial agents, are recognized as crucial for overcoming resistance. Studies investigating the enhanced efficacy of combining agents, such as bacteriophages with antibiotics, are showing promising results against challenging infections like those involving biofilms [8].
Antivirulence strategies represent a paradigm shift, aiming to disarm pathogens by targeting their disease-causing mechanisms rather than directly killing them. This approach theoretically reduces the selective pressure for resistance development. Key targets include bacterial quorum sensing, biofilm formation, and toxin production [9].
Furthermore, the emergence of resistance to traditional disinfectants used in healthcare settings is a growing concern. Research into novel antimicrobial surfaces and photocatalytic materials offers an innovative approach to preventing the transmission of HAIs by inactivating common hospital pathogens on surfaces [10].
The increasing prevalence of hospital-acquired infections (HAIs) driven by multidrug-resistant organisms (MDROs) necessitates the development of novel antimicrobial agents. This review highlights promising emerging therapies, including phage therapy, antimicrobial peptides (AMPs), and innovative small molecules targeting specific resistance mechanisms. These agents offer new avenues for combating challenging infections where conventional antibiotics are failing [1].
Phage therapy, leveraging bacteriophages to target specific bacterial pathogens, presents a viable alternative or adjunct to antibiotics for HAIs. This study details the successful application of tailored phage cocktails against multidrug-resistant *Pseudomonas aeruginosa* in a murine model, demonstrating significant bacterial load reduction and improved survival rates. The precision of phage therapy minimizes disruption to the host microbiome [2].
Antimicrobial peptides (AMPs) are a critical component of the innate immune system and show broad-spectrum activity against bacteria, fungi, and viruses. Research is focused on developing synthetic AMPs with enhanced stability and efficacy against resistant strains commonly found in HAIs, particularly methicillin-resistant *Staphylococcus aureus* (MRSA). Their ability to disrupt bacterial membranes offers a distinct mechanism of action [3].
New small molecules targeting essential bacterial pathways, such as DNA replication or cell wall synthesis, are being investigated to overcome existing resistance mechanisms. This work explores novel inhibitors of bacterial DNA gyrase and topoisomerase IV, showing potent activity against Gram-positive and Gram-negative MDROs responsible for significant HAIs, including carbapenem-resistant Enterobacteriaceae (CRE) [4].
The development of resistance to last-resort antibiotics like colistin against Gram-negative bacteria poses a critical threat. Research into novel agents that can resensitize bacteria to existing drugs or have alternative mechanisms of action is crucial. This study examines the potential of certain efflux pump inhibitors and membrane-targeting agents in combination therapies [5].
RNA interference (RNAi) technologies offer a targeted approach to inhibiting bacterial virulence factors or essential genes. This paper reviews the progress and challenges in developing RNAi-based therapeutics for HAIs, emphasizing the need for efficient delivery systems and strategies to overcome bacterial defense mechanisms [6].
The microbiome plays a crucial role in host defense against pathogens. Strategies that modulate the microbiome to prevent or treat HAIs are gaining attention. This includes the use of probiotics, prebiotics, and fecal microbiota transplantation (FMT) to restore a healthy microbial balance and enhance resistance to colonization by opportunistic pathogens [7].
Combination therapies, involving the synergistic use of existing and novel antimicrobial agents, are essential for overcoming resistance. This study investigates the enhanced efficacy of combining a novel bacteriophage with a sub-inhibitory dose of a conventional antibiotic against biofilm-forming *Staphylococcus epidermidis* relevant to prosthetic device-associated HAIs [8].
Antivirulence strategies aim to disarm pathogens by targeting their ability to cause disease rather than killing them directly. This approach could reduce the selective pressure for resistance. The review explores the potential of targeting bacterial quorum sensing, biofilm formation, and toxin production as novel therapeutic targets for HAIs [9].
The emergence of resistance to traditional disinfectants used in healthcare settings is a growing concern. This study investigates the efficacy of novel antimicrobial surfaces and photocatalytic materials for preventing the transmission of HAIs, focusing on their ability to inactivate common hospital pathogens like *Acinetobacter baumannii* and *Klebsiella pneumoniae* [10].
The rising threat of hospital-acquired infections (HAIs) driven by multidrug-resistant organisms (MDROs) necessitates novel antimicrobial strategies. Promising approaches include phage therapy for targeted bacterial elimination, and antimicrobial peptides (AMPs) with broad-spectrum activity. Novel small molecules targeting essential bacterial pathways offer another line of defense against resistant strains. Addressing resistance to last-resort antibiotics like colistin is crucial, with research focusing on resensitizing agents and alternative mechanisms. RNA interference (RNAi) provides a targeted inhibition method, while microbiome modulation through probiotics and FMT aims to bolster host defenses. Combination therapies enhance efficacy against resistant pathogens. Antivirulence strategies disarm bacteria without promoting resistance, and novel antimicrobial surfaces offer environmental control. These diverse strategies collectively aim to combat the growing challenge of HAIs.
None
None
Journal of Antimicrobial Agents received 444 citations as per Google Scholar report
